Clinical Trials Search Tool

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer’s Disease

Disease/Condition: Alzheimer’s disease

Location: Portland

Ages: 50-87

Enrollment Opens: 04-01-2022

Enrollment Closes: TBD


This trial is called the REFOCUS-ALZ trial, and is sponsored by Cassava Sciences Inc. in collaboration with Premier Research International LLC. For more information, please visit

Study ID: PTI-125-06

To Enroll: Call 503-476-9788 or schedule your free over-the-phone memory screen here:

Posted by: Center for Cognitive Health |